![Clarke Futch](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Clarke Futch
Directeur/Membre du Conseil chez
POPULATION HEALTH INVESTMENT CO., INC.
Profil
Clarke B. Futch is currently the Chairman and Chief Executive Officer at Healthcare Royalty Management LLC.
He is also the Chairman & Chief Executive Officer at Healthcare Royalty, Inc., a Director at Helomics Corp., a Director at Nuron Biotech, Inc., and an Independent Director at Population Health Investment Co., Inc. In the past, Mr. Futch has worked as a Director at Prism Pharmaceuticals, Inc., On-X Life Technologies, Inc., Suneva Medical, Inc., and Shore Therapeutics, Inc. He was also a Managing Director at Cowen Group, Inc. from 2007 to 2009.
Additionally, he served as a Non-Executive Director at HealthCare Royalty Trust PLC and as a Vice President at Raymond James Financial, Inc. from 1994 to 1999.
He was a Principal at Thomas Weisel Partners LLC and a Partner at Paul Capital Partners LP from 2001 to 2006.
Mr. Futch completed his undergraduate degree at Vanderbilt University in 1989 and obtained a doctorate degree from the University of Virginia School of Law in 1994.
Postes actifs de Clarke Futch
| Sociétés | Poste | Début |
|---|---|---|
| POPULATION HEALTH INVESTMENT CO., INC. | Directeur/Membre du Conseil | - |
Healthcare Royalty Management LLC
 Healthcare Royalty Management LLC Investment ManagersFinance Healthcare Royalty invests in companies located in the United States. The firm targets companies operating in the field of biopharmaceutical, biotechnology and medical device sectors. It provides financing for buyout transactions in the form of royalty monetization, corporate financing and debt. | Directeur Général | 01/12/2006 |
Nuron Biotech, Inc.
 Nuron Biotech, Inc. BiotechnologyHealth Technology Markets and develops vaccines for the prevention and treatment of infectious diseases | Directeur/Membre du Conseil | - |
Helomics Corp.
 Helomics Corp. Medical/Nursing ServicesHealth Services Provides cancer care development and treatment consulting services | Directeur/Membre du Conseil | - |
Healthcare Royalty, Inc.
 Healthcare Royalty, Inc. Financial ConglomeratesFinance Operates as a royalty acquisition company | Directeur Général | - |
Anciens postes connus de Clarke Futch
| Sociétés | Poste | Fin |
|---|---|---|
Cowen Group, Inc. /Old/
 Cowen Group, Inc. /Old/ Investment Banks/BrokersFinance Provides investment banking services | Corporate Officer/Principal | 04/11/2009 |
Paul Capital Partners LP
 Paul Capital Partners LP Investment ManagersFinance Paul Capital Partners' investment platforms include the Paul Capital Fund of Funds, secondary investments and commercial-stage healthcare investments. The Paul Capital Fund of Funds investment team focuses on investments in venture capital and small-cap buyouts. The firm invests in funds that support innovative products and business models. They take takes a lead investment role and actively seek advisory board seats. Their strategy is both growth and value oriented. The Paul Capital Fund of Funds venture capital investment strategy focuses on providing access to top-tier venture capital managers. The firm looks for emerging managers that have the potential to become industry leaders. They employ a multi-industry investment strategy that focuses on information technology, healthcare and clean technology. Most investments are made in early-stage companies, but some investments are made in late-stage and growth equity to provide reduced volatility and more rapid exits. The strategy is biased towards small funds and is balanced by a short list of larger funds or platforms. Paul Capital invests primarily in funds in the Silicon Valley and Boston, with growing exposure to select international investments. They make secondary investments in top tier managers obtained through the secondary market to mitigate the effect of the typical J-Curve associated with private equity fund investing. The Paul Capital Fund of Funds small-cap buyout investment strategy focuses on investments in a small-cap buyout funds in North America. They invest in small-cap buyout funds that are being raised by managers who are focused on buying companies with enterprise values of $300 million or less. To select the best performing managers, Paul Capital's process begins with a large universe of buyout relationships and ends with a focused and diversified small-cap buyout portfolio. The portfolio is complemented by co-investments and by investments in target funds obtained through the secondary market. The Paul Capital Fund of Funds co-investment strategy focuses on co-investments alongside general partners that are well-known to the firm and who require capital to close pending small-cap buyout and growth equity transactions. Investments are made directly in the securities of the portfolio company. The Fund of Funds team invests directly in portfolio companies across a full range of economic and credit cycles. For investors requiring exposure to both the firm's venture capital and small-cap buyout funds, Paul Capital provides customized solutions that allow participation in both activities over a multi-year period with a desired percentage allocation to each. Large investors seeking increased exposure to emerging managers, growth equity funds or buyout funds larger than their small-cap target (but generally less than $2 billion in size) can be accommodated through a separate account relationship. Paul Capital provides secondary transaction solutions for various sellers including pension plans, financial institutions, endowments, family offices, corporations and general partners. They help sellers reallocate their portfolio across asset types and classes, achieve early liquidity from private equity investments and obtain follow-on capital for existing portfolios and other objectives. Paul Capital Healthcare employs a variety of financing options ranging from non-dilutive financings that include royalty and revenue interest financings, to more traditional instruments such as equity and structured debt. Their clients include public and private companies, academic institutions and inventors. Paul Capital Healthcare helps companies monetize their royalty streams by selling all or a portion of these future royalties in exchange for an upfront payment and, depending on the structure, potential future payments. Paul Capital Healthcare invests in healthcare products that are approved and are generating revenue or are near commercialization. Healthcare companies should have an identifiable and established market, have patent and/or regulatory protection and be marketed by a strong organization. Paul Capital Healthcare employs the use of synthetic royalties or revenue interest financings. The firm provides a company with an upfront payment and future payments in exchange for a percentage of future product revenues. These deals are structured in a way that is similar to licensing agreements. They employ tiered revenues, reverse tiers, minimum payments, caps, step-downs and buy-out options. The deals are different from a standard licensing agreement in that Paul Capital Healthcare is not responsible for commercializing the product and is not involved in the company's daily operations. The firm makes an upfront payment to the company and, in some cases, additional payments based on certain milestones, such as regulatory approvals, patent extensions and sales targets. Paul Capital Healthcare then receives a portion of the future revenues generated by the product(s). Paul Capital Healthcare provides structured debt financing for small to mid-sized healthcare companies looking to expand operations. They can structure mezzanine-like debt in combination with revenue interests or royalty financings and the purchase of equities. Paul Capital Healthcare also structures traditional equity investments, usually in combination with revenue interest and royalty financings. The Fund participates in early-stage financing rounds in syndication with venture funds and in PIPE-style offerings. Paul Capital Healthcare focuses on near market or commercial-stage investments. | Private Equity Investor | 01/01/2006 |
| RAYMOND JAMES FINANCIAL, INC. | Private Equity Investor | 01/01/1999 |
Shore Therapeutics, Inc.
 Shore Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and supplies therapeutics | Directeur/Membre du Conseil | - |
| ░░░░░░░░░░ ░░░░░░░ ░░░░░ ░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | - |
Formation de Clarke Futch
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
86
Relations au 1er degré
16
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 16 |
|---|---|
Raymond James Financial, Inc.
 Raymond James Financial, Inc. Investment ManagersFinance Provides wealth management, investment banking and advisory services | Finance |
Prism Pharmaceuticals, Inc.
 Prism Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures cardiovascular injectibles and pharmaceutical products | Health Technology |
On-X Life Technologies, Inc.
 On-X Life Technologies, Inc. Medical SpecialtiesHealth Technology Develops, manufactures, and markets heart valve replacements | Health Technology |
Cowen Group, Inc. /Old/
Cowen Group, Inc. /Old/ Investment Banks/BrokersFinance Provides investment banking services | Finance |
Vanderbilt University
 Vanderbilt University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Thomas Weisel Partners LLC
 Thomas Weisel Partners LLC Investment Banks/BrokersFinance Provides brokerage services | Finance |
Paul Capital Partners LP
Paul Capital Partners LP Investment ManagersFinance Paul Capital Partners' investment platforms include the Paul Capital Fund of Funds, secondary investments and commercial-stage healthcare investments. The Paul Capital Fund of Funds investment team focuses on investments in venture capital and small-cap buyouts. The firm invests in funds that support innovative products and business models. They take takes a lead investment role and actively seek advisory board seats. Their strategy is both growth and value oriented. The Paul Capital Fund of Funds venture capital investment strategy focuses on providing access to top-tier venture capital managers. The firm looks for emerging managers that have the potential to become industry leaders. They employ a multi-industry investment strategy that focuses on information technology, healthcare and clean technology. Most investments are made in early-stage companies, but some investments are made in late-stage and growth equity to provide reduced volatility and more rapid exits. The strategy is biased towards small funds and is balanced by a short list of larger funds or platforms. Paul Capital invests primarily in funds in the Silicon Valley and Boston, with growing exposure to select international investments. They make secondary investments in top tier managers obtained through the secondary market to mitigate the effect of the typical J-Curve associated with private equity fund investing. The Paul Capital Fund of Funds small-cap buyout investment strategy focuses on investments in a small-cap buyout funds in North America. They invest in small-cap buyout funds that are being raised by managers who are focused on buying companies with enterprise values of $300 million or less. To select the best performing managers, Paul Capital's process begins with a large universe of buyout relationships and ends with a focused and diversified small-cap buyout portfolio. The portfolio is complemented by co-investments and by investments in target funds obtained through the secondary market. The Paul Capital Fund of Funds co-investment strategy focuses on co-investments alongside general partners that are well-known to the firm and who require capital to close pending small-cap buyout and growth equity transactions. Investments are made directly in the securities of the portfolio company. The Fund of Funds team invests directly in portfolio companies across a full range of economic and credit cycles. For investors requiring exposure to both the firm's venture capital and small-cap buyout funds, Paul Capital provides customized solutions that allow participation in both activities over a multi-year period with a desired percentage allocation to each. Large investors seeking increased exposure to emerging managers, growth equity funds or buyout funds larger than their small-cap target (but generally less than $2 billion in size) can be accommodated through a separate account relationship. Paul Capital provides secondary transaction solutions for various sellers including pension plans, financial institutions, endowments, family offices, corporations and general partners. They help sellers reallocate their portfolio across asset types and classes, achieve early liquidity from private equity investments and obtain follow-on capital for existing portfolios and other objectives. Paul Capital Healthcare employs a variety of financing options ranging from non-dilutive financings that include royalty and revenue interest financings, to more traditional instruments such as equity and structured debt. Their clients include public and private companies, academic institutions and inventors. Paul Capital Healthcare helps companies monetize their royalty streams by selling all or a portion of these future royalties in exchange for an upfront payment and, depending on the structure, potential future payments. Paul Capital Healthcare invests in healthcare products that are approved and are generating revenue or are near commercialization. Healthcare companies should have an identifiable and established market, have patent and/or regulatory protection and be marketed by a strong organization. Paul Capital Healthcare employs the use of synthetic royalties or revenue interest financings. The firm provides a company with an upfront payment and future payments in exchange for a percentage of future product revenues. These deals are structured in a way that is similar to licensing agreements. They employ tiered revenues, reverse tiers, minimum payments, caps, step-downs and buy-out options. The deals are different from a standard licensing agreement in that Paul Capital Healthcare is not responsible for commercializing the product and is not involved in the company's daily operations. The firm makes an upfront payment to the company and, in some cases, additional payments based on certain milestones, such as regulatory approvals, patent extensions and sales targets. Paul Capital Healthcare then receives a portion of the future revenues generated by the product(s). Paul Capital Healthcare provides structured debt financing for small to mid-sized healthcare companies looking to expand operations. They can structure mezzanine-like debt in combination with revenue interests or royalty financings and the purchase of equities. Paul Capital Healthcare also structures traditional equity investments, usually in combination with revenue interest and royalty financings. The Fund participates in early-stage financing rounds in syndication with venture funds and in PIPE-style offerings. Paul Capital Healthcare focuses on near market or commercial-stage investments. | Finance |
Helomics Corp.
Helomics Corp. Medical/Nursing ServicesHealth Services Provides cancer care development and treatment consulting services | Health Services |
Healthcare Royalty Management LLC
Healthcare Royalty Management LLC Investment ManagersFinance Healthcare Royalty invests in companies located in the United States. The firm targets companies operating in the field of biopharmaceutical, biotechnology and medical device sectors. It provides financing for buyout transactions in the form of royalty monetization, corporate financing and debt. | Finance |
Suneva Medical, Inc.
 Suneva Medical, Inc. Electronic Equipment/InstrumentsElectronic Technology Develops, manufactures and commercializes novel, differentiated aesthetic products | Electronic Technology |
Nuron Biotech, Inc.
Nuron Biotech, Inc. BiotechnologyHealth Technology Markets and develops vaccines for the prevention and treatment of infectious diseases | Health Technology |
Shore Therapeutics, Inc.
Shore Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and supplies therapeutics | Health Technology |
University of Virginia School of Law
 University of Virginia School of Law Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
HealthCare Royalty Trust PLC
 HealthCare Royalty Trust PLC Investment Trusts/Mutual FundsMiscellaneous Operates as a closed-ended investment fund | Miscellaneous |
Population Health Investment Co., Inc.
 Population Health Investment Co., Inc. Financial ConglomeratesFinance Operates as a special purpose acquisition company | Finance |
Healthcare Royalty, Inc.
Healthcare Royalty, Inc. Financial ConglomeratesFinance Operates as a royalty acquisition company | Finance |
